Pharmacokinetics of a single, large dose of cholecalciferol
Ilahi M, Armas LA, Heaney RP
The American journal of clinical nutrition · 150 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2008-03-01 · Am J Clin Nutr · vol. 87 · número 3 · págs. 688–691
- Editorial
- Elsevier BV
- Citado
- 201 citas · más que el 98% de estudios similares · 7.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 13 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Bone health and osteoporosis research
- Palabras clave
- vitamin D3, vitamin D supplementation, 25-hydroxyvitamin D, pharmacokinetics, intermittent dosing, dosing interval, serum vitamin D levels, seasonal variation in vitamin D, vitamin D deficiency
- MeSH
- milk, animals, humans, vitamin d deficiency, cholecalciferol, vitamin d, radioimmunoassay, skin pigmentation, area under curve, cohort studies, patient compliance, sunlight, seasons, dose-response relationship, drug, dietary supplements, adult, aged, aged, 80 and over, middle aged, female, male, bone density conservation agents, white people
3 autores
- M.A. Ilahi🇺🇸CHI Health Creighton University Medical Center - Bergan Mercy
- Laura A. G. Armas🇺🇸 · autor de correspondenciaNebraska Medical Center; CHI Health Creighton University Medical Center - Bergan Mercy
- Robert P. Heaney🇺🇸Creighton University; CHI Health Creighton University Medical Center - Bergan Mercy
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence.
Objective
The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol.
Design
One group (30 subjects) was supplemented with a single oral dose of 100,000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids.
Results
Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 27.1 +/- 7.7 ng/mL to a concentration maximum of 42.0 +/- 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 +/- 0.80 ng/mL during 4 mo.
Conclusions
Cholecalciferol (100,000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be < or =2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials.gov as #NCT00473239.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.